Mucosal Vaccination with <i>Lactococcus lactis</i>-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B <i>Streptococcus</i> in a Murine Model
Group B <i>Streptococcus</i> (GBS) is the primary etiological agent of sepsis and meningitis in newborns and is associated with premature birth and stillbirth. The development of a licensed vaccine is one of the pending challenges for the World Health Organization. Previously, we showed...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-03-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/8/2/146 |
id |
doaj-3dc01393e7eb4aa5ae875c673e13228c |
---|---|
record_format |
Article |
spelling |
doaj-3dc01393e7eb4aa5ae875c673e13228c2020-11-25T03:10:06ZengMDPI AGVaccines2076-393X2020-03-018214610.3390/vaccines8020146vaccines8020146Mucosal Vaccination with <i>Lactococcus lactis</i>-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B <i>Streptococcus</i> in a Murine ModelDiego A. Diaz-Dinamarca0Carlos Hernandez1Daniel F. Escobar2Daniel A. Soto3Guillermo A. Muñoz4Jesús F. Badilla5Ricardo A. Manzo6Flavio Carrión7Alexis M. Kalergis8Abel E. Vasquez9Sección de Biotecnología, Instituto de Salud Pública de Chile, Santiago 780050, ChileSección de Biotecnología, Instituto de Salud Pública de Chile, Santiago 780050, ChileSección de Biotecnología, Instituto de Salud Pública de Chile, Santiago 780050, ChileSección de Biotecnología, Instituto de Salud Pública de Chile, Santiago 780050, ChileSección de Biotecnología, Instituto de Salud Pública de Chile, Santiago 780050, ChileSección de Biotecnología, Instituto de Salud Pública de Chile, Santiago 780050, ChileSección de Biotecnología, Instituto de Salud Pública de Chile, Santiago 780050, ChilePrograma de Inmunología Traslacional, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago 7610315, ChileMillennium Institute of Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago 8380453, ChileSección de Biotecnología, Instituto de Salud Pública de Chile, Santiago 780050, ChileGroup B <i>Streptococcus</i> (GBS) is the primary etiological agent of sepsis and meningitis in newborns and is associated with premature birth and stillbirth. The development of a licensed vaccine is one of the pending challenges for the World Health Organization. Previously, we showed that oral immunization with surface immune protein (SIP) decreases vaginal colonization of GBS and generates functional opsonizing antibodies, which was determined by opsonophagocytic assays (OPA) in vitro. We also showed that the protein has an adjuvant vaccine profile. Therefore, an oral vaccine based on SIP may be an attractive alternative to employ in the development of new vaccines against GBS. <i>Lactococcus lactis</i> is a highlighted oral vaccine probiotic inducer of the mucosal immune response. This bacterium could serve as an antigen-delivering vehicle for the development of an edible vaccine and has been used in clinical trials. In this study, we showed that an oral vaccine with a recombinant <i>L. lactis</i> strain secreting SIP from GBS (<i>rL. lactis</i>-SIP) can induce protective humoral and cellular immunity in an experimental model of GBS vaginal colonization in C57BL/6 mice. Mice immunized with <i>rL. lactis-</i>SIP were protected against clinical symptoms and bacterial colonization after GBS vaginal colonization. Our <i>rL. lactis-</i>SIP vaccine also induces an increase of immunoglobulin G (IgG) and immunoglobulin A (IgA) specifically against SIP. The adoptive transfer of serum from vaccinated mice to naïve mice generated protection against GBS vaginal colonization. Moreover, the <i>rL.</i> <i>lactis</i>-SIP strain induces the activation of SIP-specific T cells, which could decrease GBS vaginal colonization and generate protective antibodies when transferred to other mice. Our experimental observations strongly support the notion that <i>rL. lactis</i>-SIP induces protective humoral and cellular immunity and could be considered as a novel alternative in the development of vaccines for GBS.https://www.mdpi.com/2076-393X/8/2/146group b streptococcusmucosal vaccinesurface immunogenic proteincellular immune responsehumoral immune response |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Diego A. Diaz-Dinamarca Carlos Hernandez Daniel F. Escobar Daniel A. Soto Guillermo A. Muñoz Jesús F. Badilla Ricardo A. Manzo Flavio Carrión Alexis M. Kalergis Abel E. Vasquez |
spellingShingle |
Diego A. Diaz-Dinamarca Carlos Hernandez Daniel F. Escobar Daniel A. Soto Guillermo A. Muñoz Jesús F. Badilla Ricardo A. Manzo Flavio Carrión Alexis M. Kalergis Abel E. Vasquez Mucosal Vaccination with <i>Lactococcus lactis</i>-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B <i>Streptococcus</i> in a Murine Model Vaccines group b streptococcus mucosal vaccine surface immunogenic protein cellular immune response humoral immune response |
author_facet |
Diego A. Diaz-Dinamarca Carlos Hernandez Daniel F. Escobar Daniel A. Soto Guillermo A. Muñoz Jesús F. Badilla Ricardo A. Manzo Flavio Carrión Alexis M. Kalergis Abel E. Vasquez |
author_sort |
Diego A. Diaz-Dinamarca |
title |
Mucosal Vaccination with <i>Lactococcus lactis</i>-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B <i>Streptococcus</i> in a Murine Model |
title_short |
Mucosal Vaccination with <i>Lactococcus lactis</i>-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B <i>Streptococcus</i> in a Murine Model |
title_full |
Mucosal Vaccination with <i>Lactococcus lactis</i>-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B <i>Streptococcus</i> in a Murine Model |
title_fullStr |
Mucosal Vaccination with <i>Lactococcus lactis</i>-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B <i>Streptococcus</i> in a Murine Model |
title_full_unstemmed |
Mucosal Vaccination with <i>Lactococcus lactis</i>-Secreting Surface Immunological Protein Induces Humoral and Cellular Immune Protection against Group B <i>Streptococcus</i> in a Murine Model |
title_sort |
mucosal vaccination with <i>lactococcus lactis</i>-secreting surface immunological protein induces humoral and cellular immune protection against group b <i>streptococcus</i> in a murine model |
publisher |
MDPI AG |
series |
Vaccines |
issn |
2076-393X |
publishDate |
2020-03-01 |
description |
Group B <i>Streptococcus</i> (GBS) is the primary etiological agent of sepsis and meningitis in newborns and is associated with premature birth and stillbirth. The development of a licensed vaccine is one of the pending challenges for the World Health Organization. Previously, we showed that oral immunization with surface immune protein (SIP) decreases vaginal colonization of GBS and generates functional opsonizing antibodies, which was determined by opsonophagocytic assays (OPA) in vitro. We also showed that the protein has an adjuvant vaccine profile. Therefore, an oral vaccine based on SIP may be an attractive alternative to employ in the development of new vaccines against GBS. <i>Lactococcus lactis</i> is a highlighted oral vaccine probiotic inducer of the mucosal immune response. This bacterium could serve as an antigen-delivering vehicle for the development of an edible vaccine and has been used in clinical trials. In this study, we showed that an oral vaccine with a recombinant <i>L. lactis</i> strain secreting SIP from GBS (<i>rL. lactis</i>-SIP) can induce protective humoral and cellular immunity in an experimental model of GBS vaginal colonization in C57BL/6 mice. Mice immunized with <i>rL. lactis-</i>SIP were protected against clinical symptoms and bacterial colonization after GBS vaginal colonization. Our <i>rL. lactis-</i>SIP vaccine also induces an increase of immunoglobulin G (IgG) and immunoglobulin A (IgA) specifically against SIP. The adoptive transfer of serum from vaccinated mice to naïve mice generated protection against GBS vaginal colonization. Moreover, the <i>rL.</i> <i>lactis</i>-SIP strain induces the activation of SIP-specific T cells, which could decrease GBS vaginal colonization and generate protective antibodies when transferred to other mice. Our experimental observations strongly support the notion that <i>rL. lactis</i>-SIP induces protective humoral and cellular immunity and could be considered as a novel alternative in the development of vaccines for GBS. |
topic |
group b streptococcus mucosal vaccine surface immunogenic protein cellular immune response humoral immune response |
url |
https://www.mdpi.com/2076-393X/8/2/146 |
work_keys_str_mv |
AT diegoadiazdinamarca mucosalvaccinationwithilactococcuslactisisecretingsurfaceimmunologicalproteininduceshumoralandcellularimmuneprotectionagainstgroupbistreptococcusiinamurinemodel AT carloshernandez mucosalvaccinationwithilactococcuslactisisecretingsurfaceimmunologicalproteininduceshumoralandcellularimmuneprotectionagainstgroupbistreptococcusiinamurinemodel AT danielfescobar mucosalvaccinationwithilactococcuslactisisecretingsurfaceimmunologicalproteininduceshumoralandcellularimmuneprotectionagainstgroupbistreptococcusiinamurinemodel AT danielasoto mucosalvaccinationwithilactococcuslactisisecretingsurfaceimmunologicalproteininduceshumoralandcellularimmuneprotectionagainstgroupbistreptococcusiinamurinemodel AT guillermoamunoz mucosalvaccinationwithilactococcuslactisisecretingsurfaceimmunologicalproteininduceshumoralandcellularimmuneprotectionagainstgroupbistreptococcusiinamurinemodel AT jesusfbadilla mucosalvaccinationwithilactococcuslactisisecretingsurfaceimmunologicalproteininduceshumoralandcellularimmuneprotectionagainstgroupbistreptococcusiinamurinemodel AT ricardoamanzo mucosalvaccinationwithilactococcuslactisisecretingsurfaceimmunologicalproteininduceshumoralandcellularimmuneprotectionagainstgroupbistreptococcusiinamurinemodel AT flaviocarrion mucosalvaccinationwithilactococcuslactisisecretingsurfaceimmunologicalproteininduceshumoralandcellularimmuneprotectionagainstgroupbistreptococcusiinamurinemodel AT alexismkalergis mucosalvaccinationwithilactococcuslactisisecretingsurfaceimmunologicalproteininduceshumoralandcellularimmuneprotectionagainstgroupbistreptococcusiinamurinemodel AT abelevasquez mucosalvaccinationwithilactococcuslactisisecretingsurfaceimmunologicalproteininduceshumoralandcellularimmuneprotectionagainstgroupbistreptococcusiinamurinemodel |
_version_ |
1724660561506992128 |